• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

The o2h human health EIS knowledge intensive fund

Britain’s first HMRC approved EIS knowledge intensive fund

 

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel drug discovery along with enabling services, tools and AI technologies

Email us at- invest@o2h.com
Invest
Download Info Pack

The o2h human health SEIS fund

 

 

The fund will invest in SEIS seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.

Email us at- invest@o2h.com
Invest
Download Info Pack

Fund Overview

Fund Fund Overview
Min Investment £25,000, there is no maximum investment.
Fund Size Target Fund size of £10m.
Tax Advantages If you are a UK tax payer, you may benefit from for S/EIS tax reliefs on investments.
Differentiation Grassroots working relationships providing early access to deals.
Diversification We will typically use your subscription to build a Portfolio of 5-10 unquoted and/or AIM-listed companies.
Liquidity Capital is returned to you only when we are able to sell the shares in your portfolio companies.
Expected Exit 3-7 years. o2h will seek to exit investments after 3 years to avoid losing S/EIS reliefs. The fund may hold investments longer with a view to achieving a better exit. For similar reasons we may exit businesses earlier than 3 years notwithstanding S/EIS reliefs might be lost.
Speed of Investments While we will aim to deploy capital within 12 months, we will only invest when we find suitably exciting opportunities, which may on occasion extend this period.
Risks You should only subscribe if you are able to bear losing your entire investment.

Investor Suitability

Which investor type best describes you?

I am a High Net-Worth Individual
  • I have an annual income of more than £100k or net assets of over £250k.
Review & confirm

I am a Sophisticated Investor
  • I have sufficient experience with early-stage investment to certify as a sophisticated investor.
Review & confirm

I am neither a High Net-Worth Individual nor a Self-Certified Sophisticated Investor.
  • I do not fit into either of the other categories.
Review & confirm

I am an Advisor
  • I represent a professional investor.
 Register

Self certification as a high net worth individual

I declare that I am a certified high net worth individual for the purposes of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a certified high net worth individual because at least one of the following applies

  1. the property which is my primary residence or any loan secured on that residence;

  2. any rights of mine under a qualifying contract of insurance within the meaning of the Financial Services and Markets Act 2000 (Regulated Activities) Order 2001; or

  3. any benefits (in the form of pensions or otherwise) which are payable on the termination of my service or on my death or retirement and to which I am (or my dependants are), or may be, entitled.

I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Sign by clicking here Sign by clicking here

Self certification as a sophisticated investor

I declare that I am a self-certified sophisticated investor for the purposes of the Financial Services and Markets Act (Financial Promotion) Order 2005.

I understand that this means:

  1. I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;

  2. The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;

  3. I may lose significant rights;

  4. I may have no right to complain to either of the following:

    1. the Financial Conduct Authority; or

    2. the Financial Ombudsman Scheme;

  5. I may have no right to seek compensation from the Financial Services Compensation Scheme.

I am a self-certified sophisticated investor because at least one of the following applies:

I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions.

I am aware that it is open to me to seek advice from someone who specialises in advising on investments.

Sign by clicking here Sign by clicking here

Not eligible

Sorry, you are not eligible to invest in this fund

Register as an Investor

You are not eligible to register
  • Fund overview
  • About us
  • Target areas
  • Fund reviews
  • Core team
  • Recent investments
  • Recent news
featured in
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
fund overview
The o2h Human Heath EIS Fund Launch
- Sunil Shah, CEO, o2h ventures

Therapeutics, or coming up with next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.

  • Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community.
  • Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
  • The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers.
Download the IM

EIS fund benefits

The Enterprise Investment Scheme is a government-backed initiative designed to encourage investment into unquoted and/or AIM-listed companies. It offers generous incentives in the form of tax reliefs, to investors who are prepared to take on the risks of this kind of investment.

Income Tax Relief

Loss Relief

Capital Gains tax(CGT) Relief

CGT Reinvestment Relief

Inheritance Tax(IHT) Relief

Register your interest

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

about us

The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.

our team See All
o2h-ventures

Sunil Shah

Chief Executive Officer

Sunil's Biography

o2h-ventures
close

Sunil Shah

Chief Executive Officer

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h Ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

o2h-ventures

Prashant Shah

Director

Prashant's Biography

o2h-ventures
close

Prashant Shah

Director

A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.

o2h-ventures

Andy Morley

Chief Scientific Officer

Andy's Biography

o2h-ventures
close

Andy Morley

Chief Scientific Officer

Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry.

o2h-ventures

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary's Biography

o2h-ventures
close

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland. Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market.

See All
independent reviews
o2h-ventures
MICAP – MI Capital Research
o2h-ventures
Allenbridge – Research Center
target areas
Biotech
add remove

Novel drug research for disease areas leading to breakthrough therapeutic treatments. This could be a single asset or platform technology.

AI
add remove

Using machine learning, predictive algorithms, big data and new technology to speed up or find new drug ideas and therapies.

Enablers
add remove

Technologies, specialized services or platforms that enable the success of therapeutic programs.

Oncology / Immunoncology
add remove

Oncology is the origin and development of tumours and cancer. Immunoncology works in tandem with or boosts natural immunity.

Anti-ageing
add remove

Treatments for degeneration of cells related to physical signs of ageing as well as arthritis, alzheimers, and macular degenerative diseases (wAMD).

Neuroscience
add remove

Research relating to the nervous system and the biological basis of memory, behaviour & consciousness.

Anti-Infectives
add remove

Novel approaches to ensure protection against bacterial and viral attack.

Genomics / DNA
add remove

The field of science focusing on the structure, function, evolution, mapping, and editing of genomes.

Small Molecules
add remove

Small molecule drugs help regulate a biological target such as an enzyme, channel or receptor to modify a disease process.

Biologics
add remove

Research covering proteins, blood, somatic cells, gene therapies, tissue recombinant therapeutics, and cell therapies.

Digital Therapeutics
add remove

Therapeutic interventions driven by high quality software which prevent, manage or treat a spectrum of behavioural, physical and mental conditions.

recent investments
o2h-ventures
o2h-ventures
o2h-ventures

see all

recent news
  • PharmEnable raises $7.5M in Pre-Series A funding round with a follow-on investment from o2h Ventures 29 May, 2023
  • Is Investing in SEIS ventures risky? – Join the o2h Chaitime Webinar 10 May, 2023
  • Tay Therapeutics, an o2h Ventures portfolio company secures a licensing deal worth over $65 million 5 May, 2023
fund registered with
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
You have successfully logged out!
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • PharmEnable raises $7.5M in Pre-Series A funding round with a follow-on investment from o2h Ventures
  • Is Investing in SEIS ventures risky? – Join the o2h Chaitime Webinar
  • Tay Therapeutics, an o2h Ventures portfolio company secures a licensing deal worth over $65 million
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)